Selected research
Industry Research
Histone Deacetylase (HDAC) Inhibitors Industry Research Report 2026
Market perspective
The global Histone Deacetylase (HDAC) Inhibitors market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Histone Deacetylase (HDAC) Inhibitors is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Histone Deacetylase (HDAC) Inhibitors is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Histone Deacetylase (HDAC) Inhibitors is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Histone Deacetylase (HDAC) Inhibitors include 4SC, Novartis, TetraLogic, Repligen, Onxeo, Mirati Therapeutics, MEI Pharma, Curis and CrystalGenomics, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Histone Deacetylase (HDAC) Inhibitors market in terms of revenue (US$ million) and, where applicable, sales volume (Tons), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/Tons) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Histone Deacetylase (HDAC) Inhibitors Market by Company
4SC
Novartis
TetraLogic
Repligen
Onxeo
Mirati Therapeutics
MEI Pharma
Curis
CrystalGenomics
Chroma Therapeutics
Chipscreen Biosciences
Celleron Therapeutics
Acetylon Pharmaceuticals
Histone Deacetylase (HDAC) Inhibitors Segment by Type
Benzamide
Cyclic Peptide
Hydroxamate
Fatty Acid
Histone Deacetylase (HDAC) Inhibitors Segment by Application
Treatment of Malignant Tumors
Chronic Disease Treatment
Others
Histone Deacetylase (HDAC) Inhibitors Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Histone Deacetylase (HDAC) Inhibitors market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Histone Deacetylase (HDAC) Inhibitors and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Histone Deacetylase (HDAC) Inhibitors.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Histone Deacetylase (HDAC) Inhibitors manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Histone Deacetylase (HDAC) Inhibitors by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Histone Deacetylase (HDAC) Inhibitors in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Benzamide
- Cyclic Peptide
- Hydroxamate
- Fatty Acid
Applications
- Treatment of Malignant Tumors
- Chronic Disease Treatment
- Others
Companies covered
- 4SC
- Novartis
- TetraLogic
- Repligen
- Onxeo
- Mirati Therapeutics
- MEI Pharma
- Curis
- CrystalGenomics
- Chroma Therapeutics
- Chipscreen Biosciences
- Celleron Therapeutics
- Acetylon Pharmaceuticals
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Histone Deacetylase (HDAC) Inhibitors Market Size (2021-2032)
- 2.2.2 Global Histone Deacetylase (HDAC) Inhibitors Sales (2021-2032)
- 2.2.3 Global Histone Deacetylase (HDAC) Inhibitors Market Average Price (2021-2032)
- 2.3 Histone Deacetylase (HDAC) Inhibitors by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Benzamide
- 2.3.3 Cyclic Peptide
- 2.3.4 Hydroxamate
- 2.3.5 Fatty Acid
- 2.4 Histone Deacetylase (HDAC) Inhibitors by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Treatment of Malignant Tumors
- 2.4.3 Chronic Disease Treatment
- 2.4.4 Others
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Histone Deacetylase (HDAC) Inhibitors Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Histone Deacetylase (HDAC) Inhibitors Sales (Tons) of Manufacturers (2021-2026)
- 3.3 Global Histone Deacetylase (HDAC) Inhibitors Revenue of Manufacturers (2021-2026)
- 3.4 Global Histone Deacetylase (HDAC) Inhibitors Average Price by Manufacturers (2021-2026)
- 3.5 Global Histone Deacetylase (HDAC) Inhibitors Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Histone Deacetylase (HDAC) Inhibitors, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Histone Deacetylase (HDAC) Inhibitors, Product Type & Application
- 3.8 Global Manufacturers of Histone Deacetylase (HDAC) Inhibitors, Established Date
- 3.9 Global Histone Deacetylase (HDAC) Inhibitors Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 4SC
- 4.1.1 4SC Company Information
- 4.1.2 4SC Business Overview
- 4.1.3 4SC Histone Deacetylase (HDAC) Inhibitors Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 4SC Histone Deacetylase (HDAC) Inhibitors Product Portfolio
- 4.1.5 4SC Recent Developments
- 4.2 Novartis
- 4.2.1 Novartis Company Information
- 4.2.2 Novartis Business Overview
- 4.2.3 Novartis Histone Deacetylase (HDAC) Inhibitors Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Novartis Histone Deacetylase (HDAC) Inhibitors Product Portfolio
- 4.2.5 Novartis Recent Developments
- 4.3 TetraLogic
- 4.3.1 TetraLogic Company Information
- 4.3.2 TetraLogic Business Overview
- 4.3.3 TetraLogic Histone Deacetylase (HDAC) Inhibitors Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 TetraLogic Histone Deacetylase (HDAC) Inhibitors Product Portfolio
- 4.3.5 TetraLogic Recent Developments
- 4.4 Repligen
- 4.4.1 Repligen Company Information
- 4.4.2 Repligen Business Overview
- 4.4.3 Repligen Histone Deacetylase (HDAC) Inhibitors Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Repligen Histone Deacetylase (HDAC) Inhibitors Product Portfolio
- 4.4.5 Repligen Recent Developments
- 4.5 Onxeo
- 4.5.1 Onxeo Company Information
- 4.5.2 Onxeo Business Overview
- 4.5.3 Onxeo Histone Deacetylase (HDAC) Inhibitors Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Onxeo Histone Deacetylase (HDAC) Inhibitors Product Portfolio
- 4.5.5 Onxeo Recent Developments
- 4.6 Mirati Therapeutics
- 4.6.1 Mirati Therapeutics Company Information
- 4.6.2 Mirati Therapeutics Business Overview
- 4.6.3 Mirati Therapeutics Histone Deacetylase (HDAC) Inhibitors Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Mirati Therapeutics Histone Deacetylase (HDAC) Inhibitors Product Portfolio
- 4.6.5 Mirati Therapeutics Recent Developments
- 4.7 MEI Pharma
- 4.7.1 MEI Pharma Company Information
- 4.7.2 MEI Pharma Business Overview
- 4.7.3 MEI Pharma Histone Deacetylase (HDAC) Inhibitors Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 MEI Pharma Histone Deacetylase (HDAC) Inhibitors Product Portfolio
- 4.7.5 MEI Pharma Recent Developments
- 4.8 Curis
- 4.8.1 Curis Company Information
- 4.8.2 Curis Business Overview
- 4.8.3 Curis Histone Deacetylase (HDAC) Inhibitors Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 Curis Histone Deacetylase (HDAC) Inhibitors Product Portfolio
- 4.8.5 Curis Recent Developments
- 4.9 CrystalGenomics
- 4.9.1 CrystalGenomics Company Information
- 4.9.2 CrystalGenomics Business Overview
- 4.9.3 CrystalGenomics Histone Deacetylase (HDAC) Inhibitors Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 CrystalGenomics Histone Deacetylase (HDAC) Inhibitors Product Portfolio
- 4.9.5 CrystalGenomics Recent Developments
- 4.10 Chroma Therapeutics
- 4.10.1 Chroma Therapeutics Company Information
- 4.10.2 Chroma Therapeutics Business Overview
- 4.10.3 Chroma Therapeutics Histone Deacetylase (HDAC) Inhibitors Sales, Revenue and Gross Margin (2021-2026)
- 4.10.4 Chroma Therapeutics Histone Deacetylase (HDAC) Inhibitors Product Portfolio
- 4.10.5 Chroma Therapeutics Recent Developments
- 4.11 Chipscreen Biosciences
- 4.11.1 Chipscreen Biosciences Company Information
- 4.11.2 Chipscreen Biosciences Business Overview
- 4.11.3 Chipscreen Biosciences Histone Deacetylase (HDAC) Inhibitors Sales, Revenue and Gross Margin (2021-2026)
- 4.11.4 Chipscreen Biosciences Histone Deacetylase (HDAC) Inhibitors Product Portfolio
- 4.11.5 Chipscreen Biosciences Recent Developments
- 4.12 Celleron Therapeutics
- 4.12.1 Celleron Therapeutics Company Information
- 4.12.2 Celleron Therapeutics Business Overview
- 4.12.3 Celleron Therapeutics Histone Deacetylase (HDAC) Inhibitors Sales, Revenue and Gross Margin (2021-2026)
- 4.12.4 Celleron Therapeutics Histone Deacetylase (HDAC) Inhibitors Product Portfolio
- 4.12.5 Celleron Therapeutics Recent Developments
- 4.13 Acetylon Pharmaceuticals
- 4.13.1 Acetylon Pharmaceuticals Company Information
- 4.13.2 Acetylon Pharmaceuticals Business Overview
- 4.13.3 Acetylon Pharmaceuticals Histone Deacetylase (HDAC) Inhibitors Sales, Revenue and Gross Margin (2021-2026)
- 4.13.4 Acetylon Pharmaceuticals Histone Deacetylase (HDAC) Inhibitors Product Portfolio
- 4.13.5 Acetylon Pharmaceuticals Recent Developments
5 Global Histone Deacetylase (HDAC) Inhibitors Market Scenario by Region
- 5.1 Global Histone Deacetylase (HDAC) Inhibitors Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Histone Deacetylase (HDAC) Inhibitors Sales by Region: 2021-2032
- 5.2.1 Global Histone Deacetylase (HDAC) Inhibitors Sales by Region: 2021-2026
- 5.2.2 Global Histone Deacetylase (HDAC) Inhibitors Sales by Region: 2027-2032
- 5.3 Global Histone Deacetylase (HDAC) Inhibitors Revenue by Region: 2021-2032
- 5.3.1 Global Histone Deacetylase (HDAC) Inhibitors Revenue by Region: 2021-2026
- 5.3.2 Global Histone Deacetylase (HDAC) Inhibitors Revenue by Region: 2027-2032
- 5.4 North America Histone Deacetylase (HDAC) Inhibitors Market Facts & Figures by Country
- 5.4.1 North America Histone Deacetylase (HDAC) Inhibitors Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Histone Deacetylase (HDAC) Inhibitors Sales by Country (2021-2032)
- 5.4.3 North America Histone Deacetylase (HDAC) Inhibitors Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.4.6 Mexico
- 5.5 Europe Histone Deacetylase (HDAC) Inhibitors Market Facts & Figures by Country
- 5.5.1 Europe Histone Deacetylase (HDAC) Inhibitors Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Histone Deacetylase (HDAC) Inhibitors Sales by Country (2021-2032)
- 5.5.3 Europe Histone Deacetylase (HDAC) Inhibitors Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Russia
- 5.5.9 Spain
- 5.5.10 Netherlands
- 5.5.11 Switzerland
- 5.5.12 Sweden
- 5.5.13 Poland
- 5.6 Asia Pacific Histone Deacetylase (HDAC) Inhibitors Market Facts & Figures by Country
- 5.6.1 Asia Pacific Histone Deacetylase (HDAC) Inhibitors Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Histone Deacetylase (HDAC) Inhibitors Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Histone Deacetylase (HDAC) Inhibitors Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Histone Deacetylase (HDAC) Inhibitors Market Facts & Figures by Country
- 5.7.1 South America Histone Deacetylase (HDAC) Inhibitors Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Histone Deacetylase (HDAC) Inhibitors Sales by Country (2021-2032)
- 5.7.3 South America Histone Deacetylase (HDAC) Inhibitors Revenue by Country (2021-2032)
- 5.7.4 Brazil
- 5.7.5 Argentina
- 5.7.6 Chile
- 5.8 Middle East and Africa Histone Deacetylase (HDAC) Inhibitors Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Histone Deacetylase (HDAC) Inhibitors Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Histone Deacetylase (HDAC) Inhibitors Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Histone Deacetylase (HDAC) Inhibitors Revenue by Country (2021-2032)
- 5.8.4 Egypt
- 5.8.5 South Africa
- 5.8.6 Israel
- 5.8.7 Türkiye
- 5.8.8 GCC Countries
6 Segment by Type
- 6.1 Global Histone Deacetylase (HDAC) Inhibitors Sales by Type (2021-2032)
- 6.1.1 Global Histone Deacetylase (HDAC) Inhibitors Sales by Type (2021-2032) & (Tons)
- 6.1.2 Global Histone Deacetylase (HDAC) Inhibitors Sales Market Share by Type (2021-2032)
- 6.2 Global Histone Deacetylase (HDAC) Inhibitors Revenue by Type (2021-2032)
- 6.2.1 Global Histone Deacetylase (HDAC) Inhibitors Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Histone Deacetylase (HDAC) Inhibitors Revenue Market Share by Type (2021-2032)
- 6.3 Global Histone Deacetylase (HDAC) Inhibitors Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Histone Deacetylase (HDAC) Inhibitors Sales by Application (2021-2032)
- 7.1.1 Global Histone Deacetylase (HDAC) Inhibitors Sales by Application (2021-2032) & (Tons)
- 7.1.2 Global Histone Deacetylase (HDAC) Inhibitors Sales Market Share by Application (2021-2032)
- 7.2 Global Histone Deacetylase (HDAC) Inhibitors Revenue by Application (2021-2032)
- 7.2.1 Global Histone Deacetylase (HDAC) Inhibitors Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Histone Deacetylase (HDAC) Inhibitors Revenue Market Share by Application (2021-2032)
- 7.3 Global Histone Deacetylase (HDAC) Inhibitors Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Histone Deacetylase (HDAC) Inhibitors Value Chain Analysis
- 8.1.1 Histone Deacetylase (HDAC) Inhibitors Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Histone Deacetylase (HDAC) Inhibitors Production Mode & Process
- 8.2 Histone Deacetylase (HDAC) Inhibitors Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Histone Deacetylase (HDAC) Inhibitors Distributors
- 8.2.3 Histone Deacetylase (HDAC) Inhibitors Customers
9 Global Histone Deacetylase (HDAC) Inhibitors Analyzing Market Dynamics
- 9.1 Histone Deacetylase (HDAC) Inhibitors Industry Trends
- 9.2 Histone Deacetylase (HDAC) Inhibitors Industry Drivers
- 9.3 Histone Deacetylase (HDAC) Inhibitors Industry Opportunities and Challenges
- 9.4 Histone Deacetylase (HDAC) Inhibitors Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst